ProfileGDS5678 / 1441323_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 16% 17% 17% 17% 19% 17% 18% 17% 18% 18% 17% 18% 17% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4245716
GSM967853U87-EV human glioblastoma xenograft - Control 22.4191317
GSM967854U87-EV human glioblastoma xenograft - Control 32.4212117
GSM967855U87-EV human glioblastoma xenograft - Control 42.3682417
GSM967856U87-EV human glioblastoma xenograft - Control 52.4009819
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4657917
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4548318
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.4071417
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4090118
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4192618
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4104517
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4122418
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4205517
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4143317